Profile
Trends
Explore the Research Trends
Research Network
Explore the Expert Network
Publications
-
1.
2012Piers E. M. Patten; Charles C. Chu; Emilia Albesiano; Rajendra N. Damle; Xiao-Jie Yan; Dorothy Kim; Lu Zhang; Amanda R. Magli; Jacqueline Barrientos; Jonathan E. Kolitz; et al.
Blood. 2012;120(24):4802-4811. -
2.
2012Richard Chahwan; Winfried Edelmann; Matthew D. Scharff; Sergio Roa
AIDing antibody diversity by error-prone mismatch repair
Seminars in Immunology. 2012;24(4):293-300. -
3.
2012Richard Chahwan; Johanna M.M. van Oers; Elena Avdievich; Chunfang Zhao; Winfried Edelmann; Matthew D. Scharff; Sergio Roa Roa
Journal of Experimental Medicine. 2012;209(4):671-678.
Similar Experts
- Publications
- 109










- 536










- 121










- 39










- 11










Journals
-
Publications
-
35
-
27
-
20
-
10
-
8
Grants
-
1.
Alaedini Armin; Basler Christopher F.; Belfort Marlene; Bernard Kristen A.; Bliska James B.; Bliska James Bjorn; Brady Sean F.; Briese Thomas; Buck Jochen; Califano Andrea; Casadevall Arturo; Chave Karen Judy; Crystal Ronald G.; Egan Christina; Fries Bettina; Galan Jorge E.; Garcia-Sastre Adolfo; Gulcicek Erol E.; Kielian Margaret; Levy David E.; Lipkin W Ian; MacKow Erich R.; Moscona Anne; Palacios Gustavo F.; Palese Peter; Perlin David S.; Rice Charles M.; Rose John K.; Roy Craig R.; Scharff Matthew D.; Severinov Konstantin V.; Shi Pei-Yong; Sturman Lawrence S.
9/4/2003 - 2/28/2014
Sponsor: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Funding: $ 99,943,788.00
-
2.
Scharff Matthew D.
Mismatch Repair in V region mutation and isotype switch
7/1/2003 - 12/31/2013
Sponsor: NATIONAL CANCER INSTITUTE
Funding: $ 3,083,457.00
-
3.
Scharff Matthew D.
The Production of More Effective Monoclonal Antibodies
9/1/2002 - 8/31/2005
Sponsor: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Funding: $ 501,000.00
Institutional Network
-
Internal OrganizationsShared Pub.
-
33









-
11









-
6









-
4









-
2









-
1









-
External OrganizationsShared Pub.
-
8
-
8
-
5
-
5
-
4
-
4

